Sector News

Bristol-Myers Squibb Gets Option To Buy Galecto Biotech

November 4, 2014
Life sciences
( – Bristol-Myers Squibb Co. Monday said it has received the exclusive option to acquire Galecto Biotech AB and gain worldwide rights to its lead investigational product TD139, a new inhaled inhibitor of galectin-3, in Phase 1 development for the treatment of idiopathic pulmonary fibrosis and other pulmonary fibrotic conditions.
The deal value has the potential to reach $444 million, which includes the option fee, an option exercise fee and subsequent clinical and regulatory milestone payments.
As per the agreement, Bristol-Myers can exercise the option to buy Galecto at any time following the execution of the transaction agreement, but no later than 60 days following completion of the Phase 1b trial. The companies have agreed on pre-clinical trials and a Phase 1 development plan, which will be executed by Galecto during the option period.
Francis Cuss, chief scientific officer of Bristol-Myers Squibb said: “…TD139 provides Bristol-Myers Squibb an opportunity to advance the company’s fibrosis development program with the addition of a promising compound that has the potential to modulate multiple disease pathways.”

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]